undamentalytics Newsletter
Sign in

Sophia Genetics SA (SOPH) stock

Add to watchlist

Add holding +

NASDAQ: SOPH Nasdaq Health Care Technology Next results ~November 3, 2026

C Fundamentals grade

Sophia Genetics SA is a US-listed company in the health care technology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Sophia Genetics SA is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.

Sophia Genetics SA valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 10 selling1 purchase and 150 sales by directors and officers, last 12 monthsInsider trades
  • Funds42 adding, 20 cuttingOf 14 active managers that changed their stake, 11 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Sophia Genetics SA files

Where Sophia Genetics SA stands after its latest Filing

Revenue for the twelve months was $77m, up 18.6% on a year earlier, faster than the 4.5% growth a quarter earlier. Free-cash-flow margin rose to -47.2% from -149.9% a year earlier. Operating margin widened to -91.8% from -176.7%. The diluted share count is up 2.2% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 3 of our 7 financial-health checks.

Our model value for Sophia Genetics SA is under review, so past values are not shown until it is resolved.

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 3, 2026 (estimated)

Sophia Genetics SA's trailing-twelve-month revenue grew 18.6% year on year, with a free-cash-flow margin of -47.2%. Where it stands out: change in growth rate of +14.1pp ranks 4 of 23 health care technology companies we cover. Where it lags: net margin of -102.2% ranks 20 of 23 health care technology companies we cover.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 18.5% while net income fell 26.4%: a 45pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 18.6% over the last 12 months, against a median of 8.8% for health care technology companies we cover.
  • Growth speeding up. The growth rate is 14.1 points higher than a quarter earlier.
  • Margins widening. Operating margin is up 10.4 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.0bn.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Loss-making. Operating margin is -91.8%: costs exceed revenue.
  • Burning cash. Free cash flow was -47.2% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 21.0% of revenue, against a median of 9.7% for health care technology companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 2.2% in a year.

Latest results

Earnings per share
-$0.20 against an average estimate of -$0.22: beat by 10.9%
Next report
November 3, 2026; average EPS estimate -$0.20

Sophia Genetics SA's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-6.8%
  • 1 week-5.5%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$77.3M
Operating margin
-91.8%
Net margin
-102.2%
EPS (TTM, diluted)
$-1.17

Growth

Revenue growth
+18.6%
Change in growth rate
+14.1 pts
Share count change
+2.2%

Cash

Free cash flow (TTM)
-$36.5M
FCF margin
-47.2%
Stock pay % of revenue
21.0%

News & updates

Updated November 3, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Sophia Genetics SA valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: free cash flow after stock pay is not positive.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Sophia Genetics SA as an operating company, with every model that fits that kind of business. Cost of equity 10.1%: the 10-year Treasury yield (4.9%) plus a beta of 1.15 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$0.5 ~$0.7–$4.8 Left out: out of range vs price (0.06x)
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Sophia Genetics SA with Health Care Technology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 3, 2026, before the open. Analysts expect revenue of $24m and EPS of −$0.20 (range −$0.20 to −$0.20) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.85 −7% $95m +23%
Next −$0.50 +41% $119m +25%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +9.0% on 90 days ago. In the last 30 days, 0 analysts raised Sophia Genetics SA's forecast and 1 cut it.

Consensus EPS forecast Sophia Genetics SA, last 90 days
−$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.78 Current fiscal year, 60 days ago: −$0.78 Current fiscal year, 30 days ago: −$0.78 Current fiscal year, 7 days ago: −$0.78 Current fiscal year, Now: −$0.85 −$0.85 Next fiscal year, 90 days ago: −$0.56 Next fiscal year, 60 days ago: −$0.56 Next fiscal year, 30 days ago: −$0.56 Next fiscal year, 7 days ago: −$0.56 Next fiscal year, Now: −$0.50 −$0.50

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.78−$0.56
60 days ago −$0.78−$0.56
30 days ago −$0.78−$0.56
7 days ago −$0.78−$0.56
Now −$0.85−$0.50

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.22 −$0.20 +10.9%
Mar 2026 −$0.24 −$0.19 +20.4%
Dec 2025 −$0.20 −$0.17 +14.6%
Sept 2025 −$0.20 −$0.20 +1.7%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

5 analysts, Nov 2026
Buy5100%
Hold00%
Sell00%

Monthly trend

  1. Nov 202655
  2. Oct 202655

Counts of recommendations published by analysts covering Sophia Genetics SA, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
1.3%
of tradable shares
Days to cover
1.35
at average volume
Short interest, 1 month
−6%
to October 15, 2026
Held by institutions
63%
of shares
Held by insiders
7.2%
of shares
Employees
415
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

Price behaviour

52-week range
Not enough history
From 52-week high
—
vs 50-day average
—
vs 200-day average
—
Volatility (1 year)
—
Beta vs S&P 500
—

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Sophia Genetics SA in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Sophia Genetics SA
$0 $20M $40M $60M $80M FY19 Q4 FY21 Q4 FY23 Q4 FY25 Q4 Revenue (TTM), FY19 Q4: $25.4M Revenue (TTM), FY20 Q4: $28.4M Revenue (TTM), FY21 Q4: $40.5M Revenue (TTM), FY22 Q4: $47.6M Revenue (TTM), FY23 Q4: $62.4M Revenue (TTM), FY24 Q4: $65.2M Revenue (TTM), FY25 Q4: $77.3M $77.3M

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue (TTM)
FY19 Q4 $25.4M
FY20 Q4 $28.4M
FY21 Q4 $40.5M
FY22 Q4 $47.6M
FY23 Q4 $62.4M
FY24 Q4 $65.2M
FY25 Q4 $77.3M
Revenue growth, TTM YoY Sophia Genetics SA
0% 20% 40% 60% FY20 Q4 FY21 Q4 FY22 Q4 FY23 Q4 FY24 Q4 FY25 Q4 Revenue growth, TTM YoY, FY20 Q4: 12.0% Revenue growth, TTM YoY, FY21 Q4: 42.4% Revenue growth, TTM YoY, FY22 Q4: 17.6% Revenue growth, TTM YoY, FY23 Q4: 31.1% Revenue growth, TTM YoY, FY24 Q4: 4.5% Revenue growth, TTM YoY, FY25 Q4: 18.6% 18.6%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue growth, TTM YoY
FY20 Q4 12.0%
FY21 Q4 42.4%
FY22 Q4 17.6%
FY23 Q4 31.1%
FY24 Q4 4.5%
FY25 Q4 18.6%
Operating margin (TTM) Sophia Genetics SA
-200% -150% -100% -50% 0% FY20 Q4 FY21 Q4 FY22 Q4 FY23 Q4 FY24 Q4 FY25 Q4 Operating margin (TTM), FY20 Q4: -131.6% Operating margin (TTM), FY21 Q4: -176.7% Operating margin (TTM), FY22 Q4: -184.7% Operating margin (TTM), FY23 Q4: -120.0% Operating margin (TTM), FY24 Q4: -102.1% Operating margin (TTM), FY25 Q4: -91.8% -91.8%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Operating margin (TTM)
FY20 Q4 -131.6%
FY21 Q4 -176.7%
FY22 Q4 -184.7%
FY23 Q4 -120.0%
FY24 Q4 -102.1%
FY25 Q4 -91.8%
FCF margin (TTM) Sophia Genetics SA
-200% -150% -100% -50% 0% FY19 Q4 FY21 Q4 FY23 Q4 FY25 Q4 FCF margin (TTM), FY19 Q4: -130.3% FCF margin (TTM), FY20 Q4: -113.3% FCF margin (TTM), FY21 Q4: -149.9% FCF margin (TTM), FY22 Q4: -156.0% FCF margin (TTM), FY23 Q4: -87.7% FCF margin (TTM), FY24 Q4: -68.7% FCF margin (TTM), FY25 Q4: -47.2% -47.2%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period FCF margin (TTM)
FY19 Q4 -130.3%
FY20 Q4 -113.3%
FY21 Q4 -149.9%
FY22 Q4 -156.0%
FY23 Q4 -87.7%
FY24 Q4 -68.7%
FY25 Q4 -47.2%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 20-F. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025
Income
Revenue 25 28 40 48 62 65 77
Gross profit 18 18 25 31 43 44 52
EBITDA — −35 −68 −82 −66 −58 −61
Operating income — −37 −71 −88 −75 −67 −71
Net income −34 −39 −74 −87 −79 −62 −79
Diluted EPS — −$0.93 −$1.33 −$1.36 −$1.22 −$0.95 −$1.17
Growth (year on year)
Revenue — +12.0% +42.4% +17.6% +31.1% +4.5% +18.6%
Margins
Gross margin 70.3% 62.3% 62.4% 65.7% 68.8% 67.4% 67.4%
EBITDA margin — −123.2% −167.8% −172.9% −106.6% −89.0% −79.4%
Operating margin — −131.6% −176.7% −184.7% −120.0% −102.1% −91.8%
Net margin −133.2% −138.5% −182.1% −183.9% −126.6% −95.9% −102.2%
Free-cash-flow margin −130.3% −113.3% −149.9% −156.0% −87.7% −68.7% −47.2%
Cash flow
Cash from operations −32 −32 −58 −70 −53 −45 −36
Capital spending 1 0 3 4 1 0 1
Free cash flow −33 −32 −61 −74 −55 −45 −36
Stock-based pay 1 1 9 14 15 16 16
Free cash flow after stock pay −34 −34 −69 −88 −70 −61 −53
Balance sheet
Cash 18 75 193 161 123 80 70
Total debt 4 3 0 0 0 13 48
Net debt (negative = net cash) −14 −71 −193 −161 −123 −67 −23
Diluted shares — 42m 55m 64m 65m 66m 68m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

3 of 7 checks passed · December 31, 2025
What it owns · $163m
Short-term assets $99mLonger-term assets $64m
What it owes, and who funded it · $163m
Short-term liabilities $51mLonger-term liabilities $65mShareholders' equity $47m
  • Short-term assets cover short-term liabilities $99m of assets due within a year against $51m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $99m short-term assets against $65m of longer-dated liabilities.
  • More cash than debt $70m of cash against $48m of debt.
  • Debt below 40% of shareholders' equity Debt is 101% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 0% to 101% over five years.
  • A year's operating cash flow covers at least 20% of debt −$36m of operating cash flow against $48m of debt.
  • Operating profit covers interest at least five times over Operating income of −$71m against $5m of interest.

From Sophia Genetics SA's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+2.2%
year over year
R&D spending
44.3%
of revenue
Days sales outstanding
71 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care technology
Last 12 months unless stated SOPH OPRX CCLD AMWL HCTI DH Median
Revenue, last 12 months $77m $99m $129m $219m $26m $233m $292m
Revenue growth, last 12 months 18.6% −5.8% 15.1% −19.0% 116.4% −5.0% 8.8%
Revenue growth, 3-year average — 17.0% 0.8% −7.4% −14.9% −0.8% 0.8%
Revenue growth, latest quarter — −29.8% 16.4% −26.6% 158.4% −9.1% 7.4%
Gross margin 67.4% 73.2% — — 21.5% 75.2% 58.6%
Operating margin −91.8% 11.1% 7.1% −37.3% −57.4% −104.6% −12.5%
Operating margin, 3-year average — −6.8% −7.0% −72.7% −40.6% −194.0% −18.8%
Net margin −102.2% 4.7% 6.2% −35.7% −66.3% −72.3% −12.5%
Cash from operations / revenue −46.5% 18.7% 20.8% −12.1% −62.4% 17.8% 9.7%
Free-cash-flow margin −47.2% 18.6% 17.7% −12.1% −62.4% 12.3% 9.2%
Free-cash-flow margin, 3-year average — 8.7% 16.7% −34.5% −44.7% 15.3% 8.2%
Stock pay / revenue 21.0% 8.1% 0.3% 5.9% 3.2% 10.9% 9.5%
Change in share count 2.2% 2.5% 73.1% 6.2% — −7.4% 2.9%

Median of all 23 companies we cover in health care technology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

23 health care technology companies
Measure Company Peer median Rank
Revenue growth Growth 18.6% 8.8% 7 of 23
Change in growth rate Growth +14.1pp -0.3pp 4 of 23
Gross margin Profitability 67.4% 58.2% 6 of 14
Operating margin Profitability -91.8% -6.6% 18 of 22
Net margin Profitability -102.2% -12.5% 20 of 23
Free-cash-flow margin Cash generation -47.2% 10.6% 18 of 22
Stock pay as % of revenue Cash generation 21.0% 9.7% 19 of 22
Long-term debt as % of assets Balance sheet 29.3% 20.1% 11 of 15
Change in share count Balance sheet 2.2% 2.6% 8 of 19
Days sales outstanding Balance sheet 71 days 58 days 14 of 21

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$211M
Institutions reporting
71
Shares held vs prior quarter
▲ 51.0%
Positions opened / closed
27 / 4

Top buyers and sellers, Q2 2026: 42 institutions bought and 20 sold ; the biggest buyer was Aigh Capital Management LLC (+4.0M shares) and the biggest seller Soleus Capital Management, L.P (−285K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Generation Investment Management LLP $39.2M 6.8M 18.5% 0.0%
Aigh Capital Management LLC $22.8M 4.0M 10.8% New
Akre Capital Management LLC $21.5M 3.7M 10.2% 0.0%
Royce & Associates LP $19.5M 3.4M 9.2% ▲ 86.2%
Principal Financial Group Inc $13.6M 2.4M 6.5% ▲ 67.8%
Ameriprise Financial Inc $12.8M 2.2M 6.1% New
Banque Pictet & Cie SA $12.7M 2.2M 6.0% 0.0%
Awm Investment Company, Inc. $9.8M 1.7M 4.6% New
Soleus Capital Management, L.P. $9M 1.6M 4.3% ▼ 15.4%
Silvercrest Asset Management Group LLC $8.2M 1.4M 3.9% New
Alta Wealth Advisors LLC $8.1M 1.4M 3.8% 0.0%
Kennedy Capital Management LLC $5.3M 918K 2.5% ▼ 1.1%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Sophia Genetics SA's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $99,000 1 trade by 1 insider, last 12 months Insider sales History → $5.2M 150 trades by 10 insiders · 100% under pre-set plans
Net ▼ $5.1M net selling
Insider Date Trade Shares Price Value
Xu Zhenyu Chief Scientific Officer October 13, 2026 Sell pre-set plan 4,000 $7.18 $28,727
Camblong Jurgi Executive Chairman October 12, 2026 Sell pre-set plan 8,500 $7.26 $61,671
Menu Philippe Chief Medical Officer October 12, 2026 Sell pre-set plan 5,000 $7.26 $36,303
Muken Ross Chief Executive Officer October 5, 2026 Sell pre-set plan 9,838 $8.13 $79,971
Xu Zhenyu Chief Scientific Officer October 5, 2026 Sell pre-set plan 7,394 $8.12 $60,075
Camblong Jurgi Executive Chairman October 5, 2026 Sell pre-set plan 40,172 $8.13 $326,526
Menu Philippe Chief Medical Officer October 5, 2026 Sell pre-set plan 7,394 $8.13 $60,100
Cardoza George Chief Financial Officer October 5, 2026 Sell pre-set plan 1,592 $8.10 $12,897
Puylaert Kevin Chief Sales Officer October 5, 2026 Sell 31 $7.92 $246
Puylaert Kevin Chief Sales Officer October 5, 2026 Sell 185 $8.06 $1,491
Verma Abhimanyu Chief Technology Officer October 5, 2026 Sell pre-set plan 5,284 $8.12 $42,929
Valente Manuela Chief People Officer October 5, 2026 Sell pre-set plan 4,240 $8.13 $34,487

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

Data status

When each part of this page on Sophia Genetics SA was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Sophia Genetics SA in brief

What does Sophia Genetics SA do?
Sophia Genetics SA is a US-listed company in the health care technology industry. Its financial year ends in December.
What is Sophia Genetics SA's stock ticker?
Sophia Genetics SA trades under the ticker SOPH on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Sophia Genetics SA's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Sophia Genetics SA reported revenue of $77.3M, 18.6% higher than a year earlier, according to its SEC filings.
What is Sophia Genetics SA's free cash flow?
Sophia Genetics SA's free-cash-flow margin is -47.2% of revenue over the trailing twelve months, ranking 18 of the 22 health care technology companies we cover.
Who are Sophia Genetics SA's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Generation Investment Management LLP, Aigh Capital Management LLC and Akre Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
How much debt does Sophia Genetics SA have?
Sophia Genetics SA's debt-to-equity ratio is 101.2%, from its latest balance sheet (0.5% five years earlier). The financial health section below sets out its other solvency checks.
Who are Sophia Genetics SA's competitors?
In our Health Care Technology peer group, the companies closest to Sophia Genetics SA are Optimizerx Corp, Carecloud, Inc., American Well Corp, Healthcare Triangle, Inc. and Definitive Healthcare Corp. The side-by-side comparison below sets their revenue, margins and growth against Sophia Genetics SA's.
Are insiders buying or selling Sophia Genetics SA stock?
Over the last 12 months, Sophia Genetics SA's directors and officers reported 1 open-market purchases and 150 sales on Form 4. The insider trading page charts every trade.
When is Sophia Genetics SA's next earnings date?
Around November 3, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Sophia Genetics SA announces its own schedule.